Home > Insider Trading > Filing (0001209191-21-055726)

Filing Details

Accession Number:: 0001209191-21-055726
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-13 18:24:03
Reporting Period:: 2021-09-09

Accepted Time:: 2021-09-13 18:24:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1789972	Cullinan Oncology Inc.	CGEM	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687078	Bioimpact Capital Llc	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-09-09	13,727	$29.35	7,674,449	No	4	S	Direct
Common Stock	Disposition	2021-09-10	5,931	$29.04	7,668,518	No	4	S	Direct
Common Stock	Disposition	2021-09-13	3,595	$29.10	7,664,923	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.